Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
60
GMAB Quote, Financials, Valuation and Earnings
Last price:
$33.58
Seasonality move
:
3.39%
Day range:
$33.26 - $33.67
52-week range:
$17.24 - $33.67
Dividend yield:
0%
P/E ratio:
14.29x
P/S ratio:
5.89x
P/B ratio:
3.60x
Volume:
1.4M
Avg. volume:
1.4M
1-year change:
62.09%
Market cap:
$20.7B
Revenue:
$3.1B
EPS (TTM):
$2.35
Analysts' Opinion
-
Consensus RatingGenmab A/S has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.81, Genmab A/S has an estimated upside of 12.38% from its current price of $33.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 22.73% downside risk from its current price of $33.65.
Fair Value
-
According to the consensus of 8 analysts, Genmab A/S has 12.38% upside to fair value with a price target of $37.81 per share.
GMAB vs. S&P 500
-
Over the past 5 trading days, Genmab A/S has overperformed the S&P 500 by 5.24% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Genmab A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Genmab A/S has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Genmab A/S reported revenues of $1B.
Earnings Growth
-
Genmab A/S has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Genmab A/S reported earnings per share of $0.64.
Enterprise value:
17.4B
EV / Invested capital:
2.96x
Price / LTM sales:
5.89x
EV / EBIT:
13.17x
EV / Revenue:
4.85x
PEG ratio (5yr expected):
0.11x
EV / Free cash flow:
14.34x
Price / Operating cash flow:
17.41x
Enterprise value / EBITDA:
12.54x
Gross Profit (TTM):
$3.4B
Return On Assets:
22.93%
Net Income Margin (TTM):
41.34%
Return On Equity:
28.3%
Return On Invested Capital:
27.54%
Operating Margin:
44.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $2.9B | $3.6B | $815.7M | $1B | |
| Gross Profit | $1.3B | $2.8B | $3.4B | $775.5M | $959.7M | |
| Operating Income | $886M | $931.5M | $1.3B | $312M | $457M | |
| EBITDA | -- | -- | $1.4B | $328.4M | $474.9M | |
| Diluted EPS | $0.93 | $1.04 | $2.35 | $0.29 | $0.64 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.4B | $3.8B | $4.7B | $3.5B | $4.5B | |
| Total Assets | $3.7B | $4B | $5B | $5.9B | $7B | |
| Current Liabilities | $285.2M | $393.7M | $412M | $686.4M | $741M | |
| Total Liabilities | $420.8M | $530.8M | $585.8M | $1.2B | $1.3B | |
| Total Equity | $3.3B | $3.5B | $4.4B | $4.8B | $5.8B | |
| Total Debt | $68.1M | $82.9M | $112.6M | $147.8M | $142M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $879.4M | $964.8M | $1.3B | $296.6M | $536.8M | |
| Cash From Investing | -$134.2M | -$1.5B | -$64.8M | $28.1M | -$54.2M | |
| Cash From Financing | -$64.3M | -$571.8M | -$443.5M | -$41.7M | -$19.5M | |
| Free Cash Flow | $819.5M | $940.8M | $1.2B | $289.6M | $535M | |
GMAB
Sector
Market Cap
$20.7B
$28.1M
Price % of 52-Week High
99.94%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
2.21%
-1.49%
1-Year Price Total Return
62.09%
-17.13%
Beta (5-Year)
0.902
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$32.07
200-day SMA
Buy
Level
$24.82
Bollinger Bands (100)
Buy
Level
25.61 - 32.21
Chaikin Money Flow
Buy
Level
79.6M
20-day SMA
Buy
Level
$31.86
Relative Strength Index (RSI14)
Buy
Level
66.69
ADX Line
Buy
Level
23.54
Williams %R
Sell
Level
-0.6993
50-day SMA
Buy
Level
$30.81
MACD (12, 26)
Buy
Level
0.56
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
73.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.6149)
Buy
CA Score
(Annual)
Level (2.1145)
Sell
Beneish M-Score
(Annual)
Level (12.9034)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-5.3004)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Stock Forecast FAQ
In the current month, GMAB has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The GMAB average analyst price target in the past 3 months is $37.81.
-
Where Will Genmab A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Genmab A/S share price will rise to $37.81 per share over the next 12 months.
-
What Do Analysts Say About Genmab A/S?
Analysts are divided on their view about Genmab A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Genmab A/S is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Genmab A/S's Price Target?
The price target for Genmab A/S over the next 1-year time period is forecast to be $37.81 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is GMAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Genmab A/S is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GMAB?
You can purchase shares of Genmab A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Genmab A/S shares.
-
What Is The Genmab A/S Share Price Today?
Genmab A/S was last trading at $33.58 per share. This represents the most recent stock quote for Genmab A/S. Yesterday, Genmab A/S closed at $33.65 per share.
-
How To Buy Genmab A/S Stock Online?
In order to purchase Genmab A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GMAB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GMAB
Sector
P/E ratio
14.29x
23.89x
PEG ratio
0.11x
-0.01x
P/B ratio
3.60x
1.81x
Price / LTM sales
5.89x
1.59x
Growth Metrics
GMAB
Sector
Revenue growth
24.73%
4.62%
Earnings growth
120.47%
11.06%
Revenue (5-year growth)
31.16%
6.5%
Earnings forecast
$0.45
-$0.21
Profitability
GMAB
Sector
Profitability FY 2024
$2.9B
$3.6M
Return on invested capital
27.54%
-31.84%
Return on assets
22.93%
-27.96%
Return on equity
28.3%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
GMAB
Sector
Total cash
$3.4B
$26.4M
Short term investments
$1.6B
$25.7M
Total assets
$6.4B
$76.9M
Long term debt
$142M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
